PRC1 and acute myeloid leukemia: In exploring therapeutic options for targeting PRC1, BMI1 was uncovered as an attractive target when Rizo et al. discovered that knocking down BMI1 impairs the self-renewal capacity of leukemic stem cells.99 Additionally, Shima et al. have shown that RING1A/B activity is necessary for leukemogenesis and disease progression in mouse models of AML.88 To this end, Shukla et al. sought to design small molecule inhibitors targeting PRC1.